Author

R. E. Chen

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Immunology· 9 Microbiology· 7 Cell Biology· 1

Signature Assays, Organisms & Methods

Click to filter · or open tag

Research Focus:host-pathogen & immune response· 17 Approach:experimental assay· 16 Research Focus:drug response / drug discovery· 8 Assay:proteomics· 8 Organism:human· 6 Organism:mouse· 5 Organism:non-human primate· 3 Approach:statistical model· 2

Frequent Co-Authors

M. S. Diamond· 13 shared J. B. Case· 12 shared E. S. Winkler· 5 shared J. E. Crowe· 5 shared S. P. J. Whelan· 5 shared Z. Liu· 5 shared A. O. Hassan· 4 shared D. H. Fremont· 4 shared

Activity by Year

2020-2021 · peak 9/yr

Co-Author Collaboration Network

10 top collaborators · 42 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

13 shared papersImmunology

M. S. Diamond

Mutual co-authors in cluster

Author profile →

17 papers

Recent·Most cited

A combination of two human neutralizing antibodies prevents SARS-CoV-2 infection in rhesus macaques

R. R. Cobb, J. Nkolola, P. Gilchuk, A. Chandrashekar, R. V. House, C. G. Earnhart, N. M. Dorsey, S. A. Hopkins, D. M. Snow, R. E. Chen, L. A. VanBlargan, M. Hechenblaickner, B. Hoppe, L. Collins, M. T. Tomic, , J. E. Crowe

This study shows that a combination of two human neutralizing antibodies prevents SARS-CoV-2 infection in rhesus macaques and neutralizes variants of concern in vitro.

bioRxiv · Sep 27, 2021 · PreprintImmunology

Protective activity of mRNA vaccines against ancestral and variant SARS-CoV-2 strains

B. Ying, B. Whitener, L. A. VanBlargan, A. O. Hassan, S. Shrihari, C.-Y. Liang, C. E. Karl, S. Mackin, R. E. Chen, N. M. Kafai, S. H. Wilks, D. J. Smith, J. M. Carreno, G. Singh, F. Krammer, , M. S. Diamond

This study evaluates the protective efficacy of mRNA vaccines against SARS-CoV-2 variants in mice, showing that low-dose vaccines lead to breakthrough infections with Delta variant.

bioRxiv · Aug 25, 2021Microbiology

An intranasal vaccine durably protects against SARS-CoV-2 variants in mice

A. O. Hassan, S. Shrihari, M. J. Gorman, B. Ying, D. Yuan, S. Raju, R. E. Chen, I. P. Dmitriev, E. Kashentseva, L. J. Adams, P.-Y. Shi, D. H. Fremont, D. T. Curiel, G. Alter, M. S. Diamond

This study shows that an intranasal vaccine provides durable protection against SARS-CoV-2 variants in mice, including emerging strains like B.1.351 and B.1.1.28.

bioRxiv · May 8, 2021Microbiology

A potently neutralizing anti-SARS-CoV-2 antibody inhibits variants of concern by binding a highly conserved epitope

L. VanBlargan, L. Adams, Z. Liu, R. E. Chen, P. Gilchuk, S. Raju, B. Smith, H. Zhao, J. B. Case, E. S. Winkler, B. Whitener, L. Droit, I. Aziati, P.-Y. Shi, A. Creanga, , M. Diamond

The paper identifies an antibody that neutralizes all SARS-CoV-2 variants by targeting a conserved epitope on the spike protein.

bioRxiv · Apr 26, 2021Microbiology

Efficacy and breadth of adjuvanted SARS-CoV-2 receptor-binding domain nanoparticle vaccine in macaques

H. A. D. King, M. G. Joyce, I. Elakhal Naouar, A. Ahmed, C. Macedo Cincotta, C. Subra, K. K. Peachman, H. H. Hack, R. E. Chen, P. V. Thomas, W.-H. Chen, R. S. Sankhala, A. Hajduczki, E. J. Martinez, C. E. Peterson, , L. L Jagodzinski

This study evaluates an adjuvanted SARS-CoV-2 RBD nanoparticle vaccine in macaques, showing robust immune responses and protection against viral challenge and variants.

bioRxiv · Apr 9, 2021Immunology

A public vaccine-induced human antibody protects against SARS-CoV-2 and emerging variants

A. J. Schmitz, J. S. Turner, Z. Liu, I. D. Aziati, R. E. Chen, A. Joshi, T. L. Bricker, T. L. Darling, D. C. Adelsberg, W. B. Al Soussi, J. B. Case, T. Lei, M. Thapa, F. Amanat, J. A. O'Halloran, , A. H. Ellebedy

A vaccine-induced human monoclonal antibody neutralizes SARS-CoV-2 and variants, reducing lung inflammation and viral load in hamsters.

bioRxiv · Mar 24, 2021Immunology

Efficacy of a Broadly Neutralizing SARS-CoV-2 Ferritin Nanoparticle Vaccine in Nonhuman Primates

M. G. Joyce, H. A. D. King, I. Elakhal Naouar, A. Ahmed, K. K. Peachman, C. M. Cincotta, C. Subra, R. E. Chen, P. V. Thomas, W.-H. Chen, R. S. Sankhala, A. Hajduczki, E. J. Martinez, C. E. Peterson, W. C. Chang, , N. Karasavva

A SARS-CoV-2 Spike ferritin nanoparticle vaccine induces broad neutralizing antibodies and protects nonhuman primates against respiratory infection and disease.

bioRxiv · Mar 24, 2021 · PreprintImmunology

Ultrapotent miniproteins targeting the receptor-binding domain protect against SARS-CoV-2 infection and disease in mice

J. B. Case, R. E. Chen, L. Cao, B. Ying, E. S. Winkler, I. Goreshnik, S. Shrihari, N. M. Kafai, A. L. Bailey, X. Xie, P.-Y. Shi, R. Ravichandran, L. Carter, L. Stewart, D. Baker, M. S. Diamond

This study evaluates the protective efficacy of modified miniproteins against SARS-CoV-2 in mice, showing reduced viral burden and prevention of lung disease.

bioRxiv · Mar 1, 2021Microbiology

Human neutralizing antibodies against SARS-CoV-2 require intact Fc effector functions and monocytes for optimal therapeutic protection

E. S. Winkler, P. Gilchuk, J. Yu, A. L. Bailey, R. E. Chen, S. J. Zost, H. Jang, Y. Huang, J. D. Allen, J. B. Case, R. E. Sutton, R. H. Carnahan, T. L. Darling, A. C. M. Boon, M. Mack, , M. Diamond

This study shows that neutralizing antibodies against SARS-CoV-2 need intact Fc functions and monocytes for optimal therapeutic protection in animal models.

bioRxiv · Dec 28, 2020Immunology

Cross-reactive coronavirus antibodies with diverse epitope specificities and extra-neutralization functions

A. R. Shiakolas, K. J. Kramer, D. Wrapp, S. I. Richardson, A. Schäfer, S. Wall, N. Wang, K. Janowska, K. A. Pilewski, R. Venkat, R. Parks, N. P. Manamela, N. Raju, E. Friedman Fechter, C. M. Holt, , I. S. Georgiev

The paper identifies cross-reactive antibodies against multiple coronaviruses, showing they target diverse epitopes and mediate effector functions.

bioRxiv · Dec 20, 2020 · PreprintImmunology

Landscape analysis of escape variants identifies SARS-CoV-2 spike mutations that attenuate monoclonal and serum antibody neutralization

Z. Liu, L. A. VanBlargan, L.-M. Bloyet, P. W. Rothlauf, R. E. Chen, S. Stumpf, H. Zhao, J. M. Errico, E. S. Theel, M. J. Liebeskind, B. Alford, W. J. Buchser, A. H. Ellebedy, D. H. Fremont, M. S. Diamond, S. P. J. Whelan

bioRxiv · Nov 6, 2020 · PreprintMicrobiology

A single intranasal dose of chimpanzee adenovirus-vectored vaccine confers sterilizing immunity against SARS-CoV-2 infection

A. O. Hassan, N. M. Kafai, I. P. Dmitriev, J. M. Fox, B. Smith, I. B. Harvey, R. E. Chen, E. S. Winkler, A. W. Wessel, J. B. Case, E. Kashentseva, B. T. McCune, A. L. Bailey, H. Zhao, L. A. VanBlargan, , M. S. Diamond

A single intranasal dose of ChAd-SARS-CoV-2-S vaccine prevents SARS-CoV-2 infection and likely confers sterilizing immunity in mice.

bioRxiv · Jul 16, 2020 · PreprintMicrobiology

Association between neutralizing antibodies to SARS-CoV-2 and commercial serological assays

M. S. Tang, J. B. Case, C. E. Franks, R. E. Chen, N. W. Anderson, J. P. Henderson, M. S. Diamond, A. M. Gronowski, C. W. Farnsworth

This study evaluates the association between SARS-CoV-2 neutralizing antibodies and results from three commercial serological assays, finding moderate correlations and varying agreement rates.

bioRxiv · Jul 1, 2020Immunology

Potently neutralizing human antibodies that block SARS-CoV-2 receptor binding and protect animals

S. J. Zost, P. Gilchuk, J. B. Case, E. Binshtein, R. E. Chen, J. X. Reidy, A. Trivette, R. S. Nargi, R. E. Sutton, N. Suryadevara, L. E. Williamson, E. C. Chen, T. Jones, S. Day, L. Myers, , J. E. Crowe

The paper identifies potent neutralizing antibodies against SARS-CoV-2 that block receptor binding and protect animals, providing insights for vaccine and therapy development.

bioRxiv · May 22, 2020Immunology

Neutralizing antibody and soluble ACE2 inhibition of a replication-competent VSV-SARS-CoV-2 and a clinical isolate of SARS-CoV-2.

J. B. Case, P. W. Rothlauf, R. E. Chen, Z. Liu, H. Zhao, A. S. Kim, L.-M. Bloyet, Q. Zeng, S. Tahan, L. Droit, M. X. G. Ilagan, M. A. Tartell, G. K. Amarasinghe, J. P. Henderson, S. Miersch, , S. P. J. Whelan

This study develops two neutralization assays for SARS-CoV-2 using VSV and a clinical isolate, showing high concordance between monoclonal, polyclonal antibodies, and ACE2-Fc in neutralizing activity.

bioRxiv · May 18, 2020Microbiology

Inhibition of PIKfyve kinase prevents infection by Zaire ebolavirus and SARS-CoV-2

Y.-L. Kang, Y.-Y. Chou, P. W. Rothlauf, Z. Liu, T. K. Soh, D. Cureton, J. B. Case, R. E. Chen, M. S. Diamond, S. P. J. Whelan, T. Kirchhausen

The paper shows that PIKfyve kinase inhibitors block infection by Zaire ebolavirus and SARS-CoV-2 by preventing viral content release.

bioRxiv · Apr 21, 2020Cell Biology

Structural and functional analysis of a potent sarbecovirus neutralizing antibody

D. Pinto, Y.-J. Park, M. Beltramello, A. C. Walls, M. A. Tortorici, S. Bianchi, S. Jaconi, K. Culap, F. Zatta, A. De Marco, A. Peter, B. Guarino, R. Spreafico, E. Cameroni, J. B. Case, , D. Corti

This study identifies and characterizes a potent neutralizing antibody, S309, against SARS-CoV-2 and related sarbecoviruses, showing its efficacy in preventing viral entry and potential for therapeutic use.

bioRxiv · Apr 7, 2020Immunology